Delivery of temperature sensitive items including proteins and kits will be paused on 6/19 for the Juneteenth holiday. For urgent orders please contact customer service.
Acetazolamide is a carbonicanhydrase(CA)IX inhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide has diuretic, antihypertensive and anti-gonococcal activities .
U-104 (SLC-0111) is a potent carbonicanhydrase(CA) inhibitor for CA IX and CA XII with Ki values of 45.1 nM and 4.5 nM, respectively. U-104 shows a significant delay in tumor growth in mice model .
Brinzolamide (AL-4862) is a selective carbonicanhydrase II inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research .
Benzthiazide is a long-acting diuretic and a hypertension agent. Benzthiazide is an inhibitor of carbonicanhydrase 9 (CA9), with Kis of 8.0, 8.8 and 10 nM for CA9, CA2 and CA1, respectively. Benzthiazide also suppresses proliferation of cancer cells .
Dorzolamide (L671152) hydrochloride is a potent carbonicanhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
Acetazolamide sodium is a carbonicanhydrase(CA)IX inhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide sodium has diuretic, antihypertensive and anti-gonococcal activities .
Elsulfavirine (R-1206) is an orally active human carbonicanhydrase(carbonicanhydrase, CA) inhibitor and an allosteric inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRT). Elsulfavirine also targets and blocks the interaction between adenylosuccinate lyase (ADSL) and insulin-induced gene proteins INSIG1/2, blocks SREBP-1-mediated de novo lipid synthesis, and inhibits the proliferation of liver cancer cells. The combination of Elsulfavirine and Lenvatinib (HY-10981) produces a synergistic anti-tumor effect. Elsulfavirine is converted into the active metabolite VM1500A in vivo, blocks the DNA polymerase activity of reverse transcriptase, and inhibits HIV-1 replication. Elsulfavirine exhibits a Ki of 1960 nM-52400 nM against human carbonicanhydrase isoforms including I, VII, VI, VA, VB, IX, XIII, XIV. Elsulfavirine is used in studies related to HIV-1 infection and liver cancer .
Benzenesulphonamide (Compound 1) is a carbonicanhydrase inhibitor. Benzenesulphonamide exhibits CA II inhibitory activity. Benzenesulphonamide reduces ROS and improves the gene expression of amyloid-β40 and 42. Benzenesulphonamide is beneficial for Alzheimer's disease. Benzenesulphonamide derivatives have anticancer, anti-inflammatory, and anticonvulsant activities. Benzenesulphonamide can be used in the research of Alzheimer's disease, epilepsy, inflammatory diseases, leukemia, melanoma, lung cancer, and colon cancer .
CAIX Inhibitor S4 is a potent and selective inhibitor of carbonicanhydrase IX/XII (CA IX/XII), with a Ki of 7 nM and 2 nM, respectively. CAIX Inhibitor S4 also inhibits CA II and CA I (Ki=546 and 5600 nM, respectively). CAIX Inhibitor S4 can inhibit the number of lung metastasis in orthotopic MDA-MB-231 mouse model without affecting primary tumor growth .
Benzolamide (CL11366) is a potent carbonicanhydrase(CA) inhibitor, with Kis of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a Ki of 54 nM. Benzolamide can be used for the research of glaucoma and seizures .
Acetazolamide (Standard) is the analytical standard of Acetazolamide. This product is intended for research and analytical applications. Acetazolamide is a carbonicanhydrase(CA)IX inhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide has diuretic, antihypertensive and anti-gonococcal activities .
CL 5343 (5-Amino-1,3,4-thiadiazole-2-sulfonamide) is a selective inhibitor of carbonicanhydrase B (HCA-B) and isoforms I, II, IV, and VII. CL 5343 has a Ki of 7.9 nM for hCA II. CL 5343 acts as a CA9 ligand to achieve targeted delivery of maytansine to the cell membrane of SKRC52 renal cancer cells. CL 5343 is useful in the development of therapeutics for diseases associated with CA overactivity, such as glaucoma, epilepsy, and cancer .
Enpp/Carbonicanhydrase-IN-2 (compound 1i) is a potent Enpp and carbonicanhydrase inhibitor with IC50s of 1.13, 1.07, 0.74, 0.33, 0.68 for NPP1, NPP2, NPP3, CA-IX, CA-XII respectively. Enpp/Carbonicanhydrase-IN-2 shows antiproliferative activity for cancer cells and low cytotoxic against normal cells. Enpp/Carbonicanhydrase-IN-2 induces Apoptosis .
Acetazolamide-d3 is deuterium labeled Acetazolamide (HY-B0782). Acetazolamide is a carbonicanhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide has diuretic, antihypertensive and anti-gonococcal activities.
4-(Chloromethyl)-7-hydroxycoumarin (compound 4) is a hydroxycoumarin derivative with potent antioxidant effect and high hydroxyl radical-scavenging property. 4-(Chloromethyl)-7-hydroxycoumarin contains a methyl group and a chlorine group in the heterocyclic ring. A series of coumarins incorporating hydroxy-, chloro- and/or chloromethyl-moieties has been investigated as potent inhibitors of the zinc enzyme carbonicanhydrase, expecially tumor-associated isoforms CA IX and XII .
Dorzolamide (L671152) is a potent carbonicanhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
Perfluorohexane sulfonamide (FHxSA) is the inhibitor for carbonicanhydrase, that inhibits bovine CA and human CA II with IC50 of 0.122 and 1.38 μM. Perfluorohexane sulfonamide is a delayed-action insecticide, that can be used to control red fire ants (Solenopsis invicta). Perfluorohexane sulfonamide could be a environmental pollutant .
Brinzolamide (AL-4862) hydrochloride is a selective carbonicanhydrase II inhibitor with an IC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research .
Fluorometholone acetate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester. Fluorometholone acetate potently inhibits carbonicanhydrase(CA) with IC50s of 2.18 μM and 17.5 μM for hCA-I and hCA-II, respectively. Fluorometholone acetate has anti-inflammatory effect and has the potential for external ocular inflammation research .
Zonisamide-d4 is the deuterium labeled Zonisamide. Zonisamide (AD 810) is an inhibitor of zinc enzyme carbonicanhydrase (CA), with Kis of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity. Zonisamide can be used for the rsearch for epilepsy, seizures and Parkinson's disease .
Enpp/Carbonicanhydrase-IN-1 (compound 1e) is a potent Enpp and carbonicanhydrase inhibitor with IC50s of 1.36, 1.35, 3.00, 0.88, 1.02 μM for NPP1, NPP2, NPP3, CA-II, CA-IX respectively. Enpp/Carbonicanhydrase-IN-1 shows antiproliferative activity for cancer cells and low cytotoxic against normal cells. Enpp/Carbonicanhydrase-IN-1 induces Apoptosis .
Carbonicanhydrase inhibitor 14 (Compound 8b) is a carbonicanhydrase(CA) inhibitor with Ki values of 1203, 99.7, 9.4 and 27.7 nM against hCA I, hCA II, hCA IX and hCA XII, respectively. Carbonicanhydrase inhibitor 14 can also inhibit CDK2 with an IC50 of 20.3 μM. Carbonicanhydrase inhibitor 14 shows antitumor activity .
L-650719 is a topical carbonicanhydrase inhibitor (CAI) with a Ki of 10 nM for CA II. L-650719 has shown good intraocular pressure-lowering effects in a rabbit model. L-650719 may be used in glaucoma research .
4-Acetylphenylboronic acid is a potent inhibitor of carbonicanhydrasesII(CA II), with IC50s of 246 μM and 281.40 μM for bovine CA II (bCA II) and human CA II (hCA II). 4-Acetylphenylboronic acid can be obtained via mechanochemistry and solvent evaporation. 4-Acetylphenylboronic acid has a loss of the carbonyl group at 500-550 K .
EGFR/CA-IX-IN-1 (Compound 14) is a dual inhibitor against epidermal growth factor receptor (EGFR) and carbonicanhydrase IX (CA-IX) with IC50 values of 5.92 nM and 63 nM, respectively. EGFR/CA-IX-IN-1 shows strong cytotoxicity against breast cancer cells (MDA-MB-231, MCF-7) with IC50 values of 5.78 μM and 8.05 μM, respectively. EGFR/CA-IX-IN-1 inhibits the catalytic activity of CA-IX, up-regulates BAX/Bcl-2, activates caspases, and arrests the cell cycle at the G1 phase. EGFR/CA-IX-IN-1 is promising for research of breast cancer .
Dealanylascamycin (AT-265) (Compound 2) is a nucleoside antibiotic. AT 265 is a carbonicanhydrase(CA) inhibitor, with Ki values of 167, 65.2, 234, and 143 nM for hCA I, hCA II, hCA IV, and hCA IX respectively. Dealanylascamycin is the active form of Ascamycin (HY-121071). Dealanylascamycin exhibits broad-spectrum antibacterial activity and is effective against pathogenic bacteria such as Xanthomonas citri (MIC = 0.4 μg/mL). Dealanylascamycin has high cytotoxicity .
DSR-71167 is an orally active mineralocorticoid receptor (MR) antagonist with an IC50 of 0.26 μM. DSR-71167 exhibits weak carbonicanhydrase(CA) inhibitory activity with an IC50 of 19 μM. DSR-71167 can dose-dependently increase urinary sodium excretion in rat models and has a very low risk of hyperkalemia in potassium-loading rat models. DSR-71167 lowers systolic blood pressure in hypertensive rat models. DSR-71167 can be used for research on hypertension and heart failure .
HDAC-IN-91 is a multiple inhibitor of HDAC (IC50 = 134.22 nM for HDAC1, 66.29 nM for HDAC2), carbonicanhydrase (CA) (Ki = 72.03 nM for CA IX, 50.76 nM for XII), and tubulin polymerization ( IC50 = 2.56 μM). HDAC-IN-91 inhibits PARP1 and increases the Bax/Bcl-2 ratio. HDAC-IN-91 blocks the cell cycle at the G2/M phase and induces apoptosis through a mitochondrial apoptosis activation mechanism. HDAC-IN-91 can exert potent cytotoxic activity through tubulin polymerization inhibition. HDAC-IN-91 can be used in breast, colorectal, cervical and lung cancer research .
hCAIX/XII-IN-6 is an orally active carbonicanhydrase(CA) inhibitor. hCAIX/XII-IN-6 inhibits human CA isoforms hCA I, II, IV, IX, and XII with Ki values of 6697 nM, 2950 nM, 4093 nM, 4.1 nM and 7.7 nM, respectively. hCAIX/XII-IN-6 can be used for the research of rheumatoid arthritis (RA) .
Carbonicanhydrase inhibitor 29 (Compound 5d) is an inhibitor targeting carbonicanhydrase IX(CA IX) and XII (CA XII), with inhibition constants (Ki) of 26.6 nM for CA IX and 10.9 nM for CA XII. Carbonicanhydrase inhibitor 29 can be used in anticancer research .
ALP/Carbonicanhydrase-IN-1 (Compound 1e) is a dual carbonicanhydrase(CA) and alkaline phosphatase (ALP) inhibitor. ALP/Carbonicanhydrase-IN-1 shows IC50 values of 0.44 µM, 1.61 µM, 0.51 µM, and 0.107 µM for CA-II, CA-IX, CA-XII, and ALP, respectively .
Carbonicanhydrase inhibitor 11 (compound VI) is a potent, selective carbonicanhydrase inhibitor. Carbonicanhydrase inhibitor 11 shows Ki values of 40, 39, 200 and 900 nM against CA II, IX, and XII, respectively .
Carbonicanhydrase inhibitor 12 is a potent CA II inhibitor, also has inhibitory activity in CA I (Kis of 1.72 and 271 nM in CA II and CA I, respectively). Carbonicanhydrase inhibitor 12 has potent anticancer activity against different cancer cell lines .
Carbonicanhydrase inhibitor 9 is a potent carbonicanhydrase(CA) inhibitor with Kis of 56.4 and 56.9 nM for hCA II and IX, respectively. Antiproliferative activity .
Carbonicanhydrase inhibitor 23 (compound 40) is a potent inhibitor of carbonicanhydrase(CA), with the Ki of 617.2 nM and 434.1 nM for hCA I (α) and hCA II (α), respectively .
Carbonicanhydrase inhibitor 33 (11D) is a dual inhibitor of CA(Carbonicanhydrase) IX/XII and CDK6, with Ki values of 19.7 nM and 26.1 nM for hCA IX and hCA XII, respectively. Carbonicanhydrase inhibitor 33 (11D) induces G1 arrest and apoptosis. Carbonicanhydrase inhibitor 33 (11D) can be used in the research for NSCLC .
Carbonicanhydrase/AChE-IN-2 (compound 19) is a selective acetylcholinesterase (AChE) and carbonicanhydrase(CA) inhibitor, with Ei of 5.07 nM, 24.42 nM and 19.95 nM for AChE, hCAI and hCAII, respectively .
CAII-IN-2 (compound 3g), a thiosemicarbazide derivative, is a potent, selective carbonicanhydrase-II (CA-II) inhibitor with an IC50 value of 12.1 µM for bovine CA-II. CAII-IN-2 can be used in research of carbonicanhydrase related biological disorders .
CAII-IN-1 (compound 3n), a thiosemicarbazide derivative, is a potent, selective carbonicanhydrase-II (CA-II) inhibitor with an IC50 value of 10.3 µM for bovine CA-II. CAII-IN-1 can be used in research of carbonicanhydrase related biological disorders .
TSPO/CarbonicAnhydrase Modulator 1 (Compound 3) is a dual modulator for mitochondrial translocator protein and CarbonicAnhydrase with a Ki of 1.340 μM for TSPO and a KA of 10.7 μM for CA VII. TSPO/CarbonicAnhydrase Modulator 1 promotes the production of neurosteroid, increases BDNF gene expression, exhibits neuroprotective efficacy .
O-Desmethyl Brinzolamide hydrochloride (compound 6a), an active metabolite of Brinzolamide, is a carbonicanhydrase(CA) inhibitor with a Kd of 0.136 nM for CA II and an IC50 of 165 nM for CA IV .
Carbonicanhydrase activator 1 (Compound 17) is an orally active and a BBB-penetrable Carbonicanhydrase(CA) activator with KAs of 7.8, 3.9 and 2.1 μM for hCA I, hCA VA and hCA VII. Carbonicanhydrase activator 1 can be used for cancers, glaucoma, cardiovascular diseases and neurodegenerative disorders like epilepsy research .
Carbonicanhydrase inhibitor 13 (compound 7) is a potent carbonicanhydrase(CA) inhibitor, which features 3-methylthiazolo[3,2-a]benzimidazole moiety (as a tail) connected to the zinc anchoring benzenesulfonamide moiety via ureido linker .
Carbonicanhydrase-IN-35 is a selective carbonicanhydrase(CA) inhibitor. Carbonicanhydrase-IN-35 potently inhibits tumor-associated hCA IX (Ki = 0.6 nM) and hCA XII (Ki = 2.2 nM). Carbonicanhydrase-IN-35 induces apoptosis in MCF-7 cells by elevating Bax, reducing Bcl-2, and downregulating CDK4/6. Carbonicanhydrase-IN-35 exhibits potent cytotoxicity against MCF-7 (IC50 = 0.3975 μM normoxic/0.6575 μM hypoxic), MCF-7-ADR (IC50> = 0.3975 μM normoxic/4.488 μM hypoxic), MDA-MB-231, and 4T1 breast cancer cells. Carbonicanhydrase-IN-35 can be used for the study of breast cancer .
hCAI/II-IN-7 (compound 1F) is a potent carbonicanhydrase(CA) inhibitor with Ki values of 23 nM, 44 nM and 20.57 µM for hCA-I, hCA-II and bovine CA, respectively .
Anti-inflammatory agent 67 (compound 7a) is a dual inhibitor of carbonicanhydrase and COX-2, a sulfonamide derivative of Polmacoxib (HY-16726), and has anti-inflammatory properties and analgesic activity. Anti-inflammatory agent 67 has IC50s of 10.4 μM and 50 nM for COX-1 and COX-2, respectively. The Ki of anti-inflammatory agent 67 binding to different isoforms of carbonicanhydrase are 48.3 nM (CA I), 42.2 nM (CA II), 52.3 nM (CA IX), and 13.3 nM (CA XII) .
Anti-inflammatory agent 68 (compound 7b) is a dual inhibitor of carbonicanhydrase and COX-2, a sulfonamide derivative of Polmacoxib (HY-16726), with anti-inflammatory properties and analgesic activity. Anti-inflammatory agent 68 has IC50s of 12.6 μM and 60 nM for COX-1 and COX-2, respectively. The Ki of anti-inflammatory agent 68 binding to different isoforms of carbonicanhydrase are 52.6 nM (CA I), 79.1 nM (CA II), 58.1 nM (CA IX), and 17.2 nM (CA XII) .
hCA-I/hCA-II-IN-1 (Compound P4) is a potent dual human carbonicanhydrase I (hCA-I) and human carbonicanhydrase II (hCA-II) inhibitor with Ki values of 0.22 μM and 0.33 μM, respectively. hCA-I/hCA-II-IN-1 can be used in research on diseases related to CA enzymes such as glaucoma, hypertension, and ulcers .
Benzenesulphonamide (Standard) is the analytical standard of Benzenesulphonamide. This product is intended for research and analytical applications. Benzenesulphonamide (compound 1) is a potent carbonicanhydrase inhibitor. Benzenesulphonamide shows CA II inhibitory activity .
Benzthiazide (Standard) is the analytical standard of Benzthiazide. This product is intended for research and analytical applications. Benzthiazide is a long-acting diuretic and a hypertension agent. Benzthiazide is an inhibitor of carbonicanhydrase 9 (CA9), with Kis of 8.0, 8.8 and 10 nM for CA9, CA2 and CA1, respectively. Benzthiazide also suppresses proliferation of cancer cells .
AChE/hCA I-IN-1 (Compound L3) is the inhibitor for acetylcholinesterase (AChE) and carbonicanhydrase(CA), that inhibits AChE, hCA I and hCA II with IC50 of 302, 265 and 283 nM, respectively .
Dorzolamide-d5 is the deuterium labeled Dorzolamide. Dorzolamide (L671152) is a potent carbonicanhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
DPP IV/hCA II-IN-1 is a potent and selective dipeptidyl peptidase IV (DPP IV) and carbonicanhydrase(CA) inhibitor with an IC50 value of 0.049 μM for DPP IV and with Ki values of 0.0361, 0.0428, 0.0941, 0.1328, 0.2615, and 3.034 μM for CA II, CA VB, CA VA, CA IX, CA I, and CA IV, respectively .
CA/MAO-B-IN-1 (Compound 78) is a dual inhibitor for human brain carbonicanhydrases(CA) and Monoamine Oxidase-B (MAO-B), with IC50s of 8.8 and 7.0 nM, respectively. CA/MAO-B-IN-1 reveals a human oral absorption of 71.9% through in silico prediction .
Dorzolamide (hydrochloride) (Standard) is the analytical standard of Dorzolamide (hydrochloride). This product is intended for research and analytical applications. Dorzolamide (L671152) hydrochloride is a potent carbonicanhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
CAIX/CAXII-IN-4 (Compound 7h) is the inhibitor for carbonicanhydrase(CA) that binds CA IX, CA XII and CA II with Ki of 1.324 μM, 0.435 μM and 3.035 μM. CAIX/CAXII-IN-4 exhibits board-spectrum antitumor efficacy, inhibits the proliferation of CNS cancer U251 with GI50 of 0.361 μM .
Dorzolamide-d3 hydrochloride is deuterated labeled Dorzolamide hydrochloride (HY-B0109A). Dorzolamide (L671152) hydrochloride is a potent carbonicanhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
hCAII-IN-3 (compound 7e) is a potent and selective inhibitor of carbonicanhydrase(CA II/IX) with Kis of 124.2 and 30.5 nM, respectively. hCAII-IN-3 has the potential for the research of cancer diseases .
hCAII-IN-1 (compound 7f) is a potent and selective inhibitor of carbonicanhydrase(CA II/IX) with Kis of 1.2 and 113.6 nM, respectively. hCAII-IN-1 has the potential for the research of cancer diseases .
hCAIX/XII-IN-9 (compound 8) is a potent carbonicanhydrase(CA) inhibitor with Ki values of 1658 nM, 184.8 nM, 8.9 nM, 64.8 nM for hCA I, hCA II, hCA IX, and hCA XII, respectively .
Acetazolamide- 13C2,d3 is the 13C- and deuterium labeled Acetazolamide. Acetazolamide is a carbonicanhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX . Diuretic effects .
hCAIX-IN-18 (compound 30) is an inhibitor of carbonicanhydrase(CA), with Kis of 3.5 nM, 9.4 nM, 43.0 nM and 8.2 nM for hCAI, hCAII, hCAIX, hCAXII, respectively. hCAIX-IN-18 can be used for cancer research .
Dorzolamide-d5(hydrochloride) (L671152 hydrochloride-d5) is deuterium labeled Dorzolamide (hydrochloride). Dorzolamide (L671152) hydrochloride is a potent carbonicanhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
hBChE-IN-3 (compound 30) is a combination of carbonicanhydrase (CA) activator and cholinesterase (ChE) inhibitor with IC50 values of 7.4 and 1.9 nM for AchE and BchE, respectively. hBChE-IN-3 can be used in the study of neurodegeneration and psychiatric disorders .
JNJ-26990990 is a broad-spectrum antiepileptic agent with oral activity. JNJ-26990990 can inhibit voltage-gated Na + channels and N-type Ca2+ channels, but has a very weak inhibitory effect on human carbonicanhydrase-II (IC50 = 110 μM) .
Chlorzolamide (CL 13580) is a carbonicanhydrase(CA) inhibitor. Chlorzolamide has an effect on the skeletal muscle of rats, which can reduce the tetanic contraction force of soleus and extensor digitorum longus and prolong the relaxation time and peak time of muscle contraction. In addition, Chlorzolamide inhibits tumor cell proliferation and has antitumor activity .
Brinzolamide-d5 (hydrochloride) is the deuterium labeled Brinzolamide hydrochloride . Brinzolamide (AL-4862) hydrochloride is a selective carbonicanhydrase II inhibitor with an IC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research .
CAXII-IN-3 is an effective carbonicanhydrase(CA XII) inhibitor with a Ki of 53 nM. CAXII-IN-3 exhibits selective inhibition against multiple human CA subtypes with Kis of 5.3 μM, 75 nM, 1.9 μM, > 10 μM against CA I, CA II, CA IV and CA IX. CAXII-IN-3 mainly inhibits CA II and XII, and reduces aqueous humor production. CAXII-IN-3 exhibits β3-AR agonistic activity, can dilate retinal blood vessels, and improve optic nerve perfusion. CAXII-IN-3 can be used in the research of ocular disorders such as glaucoma .
Brinzolamide (Standard) is the analytical standard of Brinzolamide. This product is intended for research and analytical applications. Brinzolamide (AL-4862) is a selective carbonicanhydrase II inhibitor with anIC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide can be used in glaucoma disease research .
Benzolamide (Standard) is the analytical standard of Benzolamide. This product is intended for research and analytical applications. Benzolamide (CL11366) is a potent carbonicanhydrase (CA) inhibitor, with Kis of 15 nM, 9 nM, 94 nM and 78 nM for hCA I, hCA II, EcoCAγ and VchCAγ, respectively. Benzolamide also inhibits CAS3, with a Ki of 54 nM. Benzolamide can be used for the research of glaucoma and seizures .
CA IX/VEGFR-2-IN-3 (Compound 6i) is an inhibitor of CarbonicAnhydrase IX and VEGFR-2, with IC50 values of 41 and 48 nM, respectively. CA IX/VEGFR-2-IN-3 exhibits anticancer activity, inhibiting the growth of MCF-7 breast cancer cells (with an IC50 of 22.33 μM) and mouse fibroblast cell line 3T3 (where cell viability is less than 40% at a concentration of 100 μM). CA IX/VEGFR-2-IN-3 can be used for research in the field of cancer treatment .
hCAIX/XII-IN-5 (Coumarin 9a) a carbonicanhydrase(CA) inhibitor, and exhibits excellent hCA IX/XII selectivity (Ki=93.9 and 85.7 nM, respectively) over hCA I and hCA II. hCAIX/XII-IN-5 shows anti-proliferative activities to cancer cells. hCAIX/XII-IN-5 can delay cell cycle and induce apoptosis .
Fluorometholone acetate (Standard) is the analytical standard of Fluorometholone acetate. This product is intended for research and analytical applications. Fluorometholone acetate is a synthetic glucocorticoid corticosteroid and a corticosteroid ester. Fluorometholone acetate potently inhibits carbonicanhydrase (CA) with IC50s of 2.18 μM and 17.5 μM for hCA-I and hCA-II, respectively. Fluorometholone acetate has anti-inflammatory effect and has the potential for external ocular inflammation research .
CA IX-IN-2 (Compound 9o) is an inhibitor for carbonicanhydrase(CA), that inhibits CA IX, CA XII and CA II with an IC50 of 5.6, 7.4 and 430 nM, respectively. CA IX-IN-2 inhibits the proliferation of cancer cell HCT-116, SW480, MDA-MB 231 and MCF-7, with IC50s of 14.63-29.33 μM. CA IX-IN-2 intercalates DNA, arrests cell cycle at G1/S phase, and induces apoptosis in MDA-MB-231. CA IX-IN-2 affects the mitochondrial membrane potential (MMP), increases the intracellular ROS levels, causes mitochondrial damage, and inhibits the cell migration of MDA-MB-231. CA IX-IN-2 exhibits antitumor efficacy in mouse models .
hCAIX/XII-IN-8 (compound 3g) is a potent human (carbonicanhydrase) CA IX and XII inhibitor, with Ki values of 8.5 and 6.7 nM, respectively. hCAIX/XII-IN-8 shows particularly strong inhibitory activity against the tumor-associated membrane-bound isoforms, hCA IX and XII, while maintaining a high selectivity ratio over cytosolic off-target isoforms hCA I and II .
hCA/VEGFR-2-IN-1 (compound 13a) is a potent dual CarbonicAnhydrase(CA) IX/XII with Ki values of 4.7 nM and 8.3 nM for hCA XII and hCA IX, respectively. hCA/VEGFR-2-IN-1 (compound 13a) is a potent VEGFR-2 inhibitor with IC50 values 26.3 nM. hCA/VEGFR-2-IN-1 has anticancer activity .
CL 5343 (Standard) is the analytical standard of CL 5343. This product is intended for research and analytical applications. CL 5343 (5-Amino-1,3,4-thiadiazole-2-sulfonamide) is an inhibitor of human carbonicanhydrase B (HCA-B). CL 5343 can serve as a CA9 ligand to achieve the targeted delivery of maytansinoid to the cell membrane of SKRC52 renal cancer cells .
Antibacterial agent 215 (Compound 3b) is an inhibitor for carbonicanhydrase(CA), with Ki of 17.61, 5.14 and 43.74 nM, for hCA I, hCA II and AChE, respectively. Antibacterial agent 215 exhibits anti-tuberculosis, with MIC of 62.5 µg/ml against M. tuberculosis. Antibacterial agent 215 exhibits antifungal activities against Candida spp. strains ATCC 14053, ATCC 1369, and ATCC 15126, with MICs of 125 µg/ml .
CAIX/CDK-2-IN-1 is a dual-acting inhibitor of carbonicanhydrase IX(CA IX) and cyclin-dependent kinase-2 (CDK-2) with IC50 values of 0.29 μM and 0.32 μM. The zein nanoparticls of CAIX/CDK-2-IN-1 can induce cancer cells apoptosis. CAIX/CDK-2-IN-1 can be used for the research of cancer, such as lung cancer .
hCAI/II-IN-6 is an orally active human carbonicanhydrase (CA) inhibitor. hCAI/II-IN-6 selectively inhibits hCA II and hCA VII isoforms with Ki values of 220, 4.9, 6.5 and ＞50000 nM for hCA I, hCA II , hCA VII and hCA XII respectively. hCAI/II-IN-6 shows anticonvulsant activity and anti maximal electroshock (MES) activity in vivo. hCAI/II-IN-6 can be used for the research of epilepsy .
hCAIX/XII-IN-13 is an inhibitor of human carbonicanhydrases (hCA). hCAIX/XII-IN-13 shows good inhibitory activity against the tumor-related CA subtypes IX and XII, with Ki values of 0.08 µM and 0.06 µM, respectively. Under hypoxic conditions, hCAIX/XII-IN-13 can restore the cytotoxicity of Doxorubicin (HY-15142A) on MCF-7 cells, increasing G2/M phase cell cycle arrest and apoptosis .
Chlorthalidone Impurity G (Chlorthalidone EP Impurity G) is a potential impurity found in commercial preparations of chlorthalidone with moderate antihypertensive effects. Chlorthalidone is a thiazide diuretic that inhibits the Na+/Cl- cotransporter in the distal tubule of the kidney, thereby preventing sodium and chloride reabsorption, resulting in decreased plasma volume and cardiac output. It also inhibits carbonicanhydrase (CA), including isoenzymes CAVB, VII, IX, XII, and XIII (Kis=2.8-23 nM) and to a lesser extent CAI, CAII, IV, VA, and VI (Ki=138-1,347 nM), mediating vasodilatory activity.
Benzenesulphonamide (Standard) is the analytical standard of Benzenesulphonamide (HY-101087). This product is intended for research and analytical applications. Benzenesulphonamide (Compound 1) is a carbonicanhydrase inhibitor. Benzenesulphonamide exhibits CA II inhibitory activity. Benzenesulphonamide reduces ROS and improves the gene expression of amyloid-β40 and 42. Benzenesulphonamide is beneficial for Alzheimer's disease. Benzenesulphonamide derivatives have anticancer, anti-inflammatory, and anticonvulsant activities. Benzenesulphonamide can be used in the research of Alzheimer's disease, epilepsy, inflammatory diseases, leukemia, melanoma, lung cancer, and colon cancer .
Carbonicanhydrase-IN-37 (compound 9a) is a potent and orally active carbonicanhydrase(CA) inhibitor with Kis of 9.7 and 1.0 nM for hCA VA and hCA VB, respectively. Carbonicanhydrase-IN-37 shows anti allodynic and antihyperalgesic effects on Paclitaxel (HY-B0015)-induced neuropathic pain in mice. Carbonicanhydrase-IN-37 can be used for neuropathic pain research .
Catechol diacetate (Compound 15) is a carbonicanhydrase(CA) inhibitor. Catechol diacetate is promising for research of glaucoma, epilepsy, edema, and cancer .
Thioaspirine is a carbonicanhydrase(CA) inhibitor with Kis of 64.3 and 10.9 μM for hCA II and hCA IX, respectively. Thioaspirine effectively relieves the inflammatory pain in CFA (HY-153808)-treated mice. Thioaspirine can be used for inflammatory pain research .
CA IX-IN-5 (compound 9) is a human carbonicanhydrase IX (hCA IX) inhibitor with a Ki of 7.4 nM against hCA IX and 25.0 nM against hCA II.CA IX-IN-5 functionally inhibits hCA IX and hCA II isoenzymes, with selectivity for hCA IX over hCA II.CA IX-IN-5 can be used for the research of breast, colorectal, glioblastoma, lung, head and neck, and cervical cancers .
ts-SA is a carbonicanhydrase (CA) inhibitor with activity against seven human CA homologues. ts-SA can bind to the Zn(II) ion in the enzyme active site in a deprotonated form. The organic skeleton of ts-SA extends in the enzyme cavity and participates in multiple interactions with amino acid residues and water molecules. Due to its structural differences, the inhibitory performance of ts-SA is significantly better than that of another pyridine derivative. ts-SA exhibits low nanomolar inhibitory activity and is a multi-target CA inhibitor .
PDE5/CA-IN-1 is a dual PDE5 and carbonicanhydrase(CA) inhibitor, with IC50 values of 0.41, 38.4, and 9.1 nM against PDE5, hCA II, and hCA VA, respectively. PDE5/CA-IN-1 inhibits multiple hCA subtypes associated with Alzheimer's disease. As a cytoprotective agent and oxidative stress alleviator, PDE5/CA-IN-1 reduces oxidative stress, and prevents recognition memory and working memory impairments. PDE5/CA-IN-1 is available for the research of Alzheimer's disease .
Elsulfavirine sodium (R-1206) is an orally active human carbonicanhydrase(carbonicanhydrase, CA) inhibitor and an allosteric inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRT). Elsulfavirine sodium also targets and blocks the interaction between adenylosuccinate lyase (ADSL) and insulin-induced gene proteins INSIG1/2, blocks SREBP-1-mediated de novo lipid synthesis, and inhibits the proliferation of liver cancer cells. The combination of Elsulfavirine sodium and Lenvatinib (HY-10981) produces a synergistic anti-tumor effect. Elsulfavirine sodium is converted into the active metabolite VM1500A in vivo, blocks the DNA polymerase activity of reverse transcriptase, and inhibits HIV-1 replication. Elsulfavirine sodium exhibits a Ki of 1960 nM-52400 nM against human carbonicanhydrase isoforms including I, VII, VI, VA, VB, IX, XIII, XIV. Elsulfavirine sodium is used in studies related to HIV-1 infection and liver cancer .
CAIX/XII-IN-17 is a selective human carbonicanhydrase IX/XII(CA IX/XII) inhibitor with Ki values of 25.1 nM (hCA IX) and 35.2 nM (hCA XII). CAIX/XII-IN-17 induces apoptosis in pancreatic cancer cells. CAIX/XII-IN-17 can be used for the research of breast cancer, pancreatic cancer .
CAIX/XII-IN-18 is a selective human carbonicanhydrase IX/XII (CA IX/XII) inhibitor with Ki values of 28.1 nM (hCA IX) and 11.6 nM (hCA XII). CAIX/XII-IN-18 induces apoptosis in breast cancer cells. CAIX/XII-IN-18 can be used for the research of breast cancer, pancreatic cancer .
Elsulfavirine (Standard) is the analytical standard of Elsulfavirine (HY-109056). This product is intended for research and analytical applications. Elsulfavirine (R-1206) is an orally active human carbonicanhydrase (carbonicanhydrase, CA) inhibitor and an allosteric inhibitor of HIV-1 non-nucleoside reverse transcriptase (NNRT). Elsulfavirine also targets and blocks the interaction between adenylosuccinate lyase (ADSL) and insulin-induced gene proteins INSIG1/2, blocks SREBP-1-mediated de novo lipid synthesis, and inhibits the proliferation of liver cancer cells. The combination of Elsulfavirine and Lenvatinib (HY-10981) produces a synergistic anti-tumor effect. Elsulfavirine is converted into the active metabolite VM1500A in vivo, blocks the DNA polymerase activity of reverse transcriptase, and inhibits HIV-1 replication. Elsulfavirine exhibits a Ki of 1960 nM-52400 nM against human carbonicanhydrase isoforms including I, VII, VI, VA, VB, IX, XIII, XIV. Elsulfavirine is used in studies related to HIV-1 infection and liver cancer .
CAII-IN-15 is a potent carbonicanhydrase II (CA II) inhibitor with a hCA IIIC50 of 10 nM. CAII-IN-15 elevates cGMP levels, releases nitric oxide, reduces oxidative stress, and exhibits neuroprotective activity in vitro. CAII-IN-15 inhibits NLRP3 inflammasome activation, reduces neuronal apoptosis. CAII-IN-15 reduces Intraocular pressure (IOP) in rabbits. CAII-IN-15 can be used for the research of glaucoma .
Xipamide is an orally active carbonicanhydrase(CA) inhibitor and Na +/Cl --potassium transporter inhibitor with diuretic and antihypertensive effects. Xipamide reduces NaCl reabsorption by inhibiting the Cl -/NaCO3- anion exchanger, and increases calcium reabsorption while promoting potassium and magnesium excretion. Xipamide is mainly cleared via the renal pathway and causes a temporary decrease in glomerular filtration rate under specific conditions. Xipamide does not affect Ca2+ signaling induced by endothelin-1 and other factors, nor does it inhibit various ion cotransport or pump activities in red blood cells. Xipamide can be used in researches related to cardiovascular diseases, hypertension (especially with left ventricular hypertrophy), advanced renal failure, and liver cirrhosis with ascites .
CAII-IN-12 (compound 6c) is a potent and selective carbonicanhydrase(CA)II and VII inhibitor (hCA IIKi = 47.8 nM, hCA VIIKi = 3.6 nM) with anti-epilepitic activity. CAII-IN-12 displays selectivity over hCA I (Ki = 370 nM). CAII-IN-12 exhibits potent anticonvulsant activity in both Pentylenetetrazol- and Pilocarpine (HY-B0726A)-induced seizure mouse models. CAII-IN-12 increases expression of KCC2 in the hippocampus, maintains neuronal integrity, and reduces mTOR activity. CAII-IN-12 can be used for epilepsy research .
Multi-kinase-IN-8 is a muti-kinase inhibitor. Multi-kinase-IN-8 inhibits COX-1 (IC50 of 12.6 μM), COX-2 (IC50 of 0.05 μM) and VEGFR-2 (IC50 of 0.12 nM). Multi-kinase-IN-8 inhibits tumor-associated carbonicanhydrases(CA IX and CA XII with Ki of 31.5 nM and 386.9 nM, respectively). Multi-kinase-IN-8 triggers cell cycle arrest and apoptosis through upregulation of Caspase 9 and Bax along with downregulation of Bcl 2. Multi-kinase-IN-8 suppresses PGE2, p-VEGFR-2, MMP-9 and HIF-1α and exhibits growth-inhibitory activity against breast cancer, lung cancer, and colorectal adenocarcinoma .
Benzenesulphonamide (Standard) is the analytical standard of Benzenesulphonamide. This product is intended for research and analytical applications. Benzenesulphonamide (compound 1) is a potent carbonicanhydrase inhibitor. Benzenesulphonamide shows CA II inhibitory activity .
Carbonic Anhydrase 2 (CA2) catalyzes the reversible hydration of carbon dioxide. Mutations in CA2 are linked to osteopetrosis and renal tubular acidosis. The gene exhibits biased expression in various tissues, notably in the stomach and colon. Two transcript variants, encoding different isoforms, have been identified. Carbonic Anhydrase 2 Protein, Human (His) is the recombinant human-derived Carbonic Anhydrase 2 protein, expressed by E. coli , with C-6*His labeled tag.
Carbonic Anhydrase 2 (CA2) catalyzes the reversible hydration of carbon dioxide. Mutations in CA2 are linked to osteopetrosis and renal tubular acidosis. The gene exhibits biased expression in various tissues, notably in the stomach and colon. Two transcript variants, encoding different isoforms, have been identified. Carbonic Anhydrase 2 Protein, Human (C-His, Solution) is the recombinant human-derived Carbonic Anhydrase 2 protein, expressed by E. coli , with C-His labeled tag.
Carbonic Anhydrase 2 Protein is a member of the carbonic anhydrase isozyme family, responsible for catalyzing the reversible hydration of carbon dioxide. Mutations in CA2 are linked to osteopetrosis and renal tubular acidosis. The gene exhibits biased expression in various tissues, notably in the stomach and colon. CA2 plays vital role in the regulation of ion transport and pH balance and is involved in many biological processes. Carbonic Anhydrase 2 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Carbonic Anhydrase 2 protein, expressed by HEK293 , with C-His labeled tag.
The carbonic anhydrase 14 (CA14) protein catalyzes the reversible hydration of carbon dioxide, converting it into bicarbonate ions and protons.Its enzymatic activity is essential for physiological processes, regulating pH and maintaining acid-base balance.Carbonic Anhydrase 14 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Carbonic Anhydrase 14 protein, expressed by HEK293 , with C-6*His labeled tag.
CA12 (or carbonic anhydrase 12) plays a crucial role in the reversible hydration of carbon dioxide, catalyzing its conversion into bicarbonate ions and protons. This enzymatic activity is essential for key physiological processes, including regulating pH and maintaining acid-base balance. CA12/Carbonic Anhydrase 12 Protein, Human (HEK293, His) is the recombinant human-derived CA12/Carbonic Anhydrase 12 protein, expressed by HEK293 , with C-His labeled tag.
CA5A protein is a mitochondrial carbonic anhydrase that catalyzes the reversible conversion of carbon dioxide to bicarbonate/HCO3, providing essential bicarbonate for mitochondrial enzymes. Impermeable mitochondria rely on CA5A to support enzymatic reactions critical to intermediary metabolism, including the urea cycle and the Krebs cycle. CA5A Protein, Human (His) is the recombinant human-derived CA5A protein, expressed by E. coli , with N-Met, C-His labeled tag.
Despite its name, the carbonic anhydrase VIII (CA8) protein lacks carbonic anhydrase catalytic activity. This distinguishes CA8 from its typical functions related to carbonic anhydrase, an enzyme known for its ability to catalyze the reversible hydration of carbon dioxide. Carbonic Anhydrase 8 Protein, Mouse (His) is the recombinant mouse-derived Carbonic Anhydrase VIII/CA8 protein, expressed by E. coli , with C-His labeled tag.
Carbonic anhydrase 4 catalyzes the reversible hydration of carbon dioxide and plays a crucial role in maintaining intracellular and extracellular pH. Carbonic Anhydrase 4 Protein, Human (HEK293, His) is the recombinant human-derived Carbonic Anhydrase 4 protein, expressed by HEK293 , with C-His labeled tag.
Carbonic Anhydrase 14 Protein catalyzes the reversible hydration of carbon dioxide, converting it to bicarbonate ions and protons, and vice versa. Its vital enzymatic activity contributes to physiological processes, regulating acid-base balance, respiration, and cellular pH homeostasis. The protein plays a pivotal role in carbon dioxide transport and metabolism in the body. Carbonic Anhydrase 14 Protein, Human (HEK293, His) is the recombinant human-derived Carbonic Anhydrase 14 protein, expressed by HEK293 , with C-His labeled tag.
Carbonic Anhydrase VIII/CA8 Protein, Human (His) expresses in E. coli with a His tag at the N-terminus. Carbonic anhydrase 8 (CA8), an isozyme of α-carbonic anhydrases (CAs), is an allosteric inhibitor of inositol trisphosphate receptor-1 (ITPR1), which regulates neuronal intracellular calcium release.
Carbonic Anhydrase 1 Protein, Human (His, solution) expresses in E. coli with a His tag at the N-terminus. Carbonic Anhydrase 1 (CA1) expression and CA1-mediated calcification are significantly associated with atherosclerosis (AS) progression.
Carbonic Anhydrase 3 Protein, Human (His) expresses in E. coli with a His tag at the N-terminus. Carbonic anhydrase 3 (CA III) is a zinc metalloenzyme known to catalyze the reversible hydration of CO2 to HCO3-.
Carbonic Anhydrase 4 Protein, Human (His) a recombinant Mouse Carbonic Anhydrase 4 produced in E. coli, has a His tag at the N-terminus. The Carbonic Anhydrase 4 (CA4) protein is a zinc metalloenzyme that catalyzes the reversible hydration and dehydration of CO2 and HCO3-.
Carbonic Anhydrase VII/CA7 Protein, Human (His) expresses in E. coli with a His tag at the N-terminus. Human carbonic anhydrase VII (hCA VII) is a cytosolic isoform belonging to the α-CA family that shows high carbon dioxide hydration activity.
Carbonic Anhydrase 13 Protein, Human (His) expresses in E. coli with a His tag at the N-terminus. Human Carbonic Anhydrase 13, a member of the human carbonic anhydrase (hCA), can control pH and ion balance regulation.
Carbonic Anhydrase 14 Protein, Mouse (His) is an approximately 40.0 kDa mouse carbonic anhydrase 14 protein with a His-flag. Carbonic Anhydrase 14 is a type I membrane enzyme highly expressed in all parts of the central nervous system.
CA12/Carbonic Anhydrase 12 Protein, Mouse (HEK293, His), a recombinant Mouse Carbonic Anhydrase 12 produced in HEK293 cells, has a His tag at the N-terminus. Hypoxic tumors overexpress two carbonic anhydrases (CA), CA IX and XII, involved in complex processes connected to tumorigenesis (pH regulation, metabolism, invasion, and dissemination of the tumor).
The carbonic anhydrase 9 (CA9) protein plays a crucial role as a catalyst in the conversion of carbon dioxide and water. It promotes the formation of bicarbonate and hydrogen ions (dissociated ions of carbonic acid). Carbonic Anhydrase 9 Protein, Human (HEK293, Fc) is the recombinant human-derived Carbonic Anhydrase 9 protein, expressed by HEK293 , with C-hFc labeled tag.
The carbonic anhydrase 9 (CA9) protein plays a crucial role as a catalyst in the conversion of carbon dioxide and water. It promotes the formation of bicarbonate and hydrogen ions (dissociated ions of carbonic acid). Carbonic Anhydrase 9 Protein, Canine (HEK293, His) is the recombinant canine-derived Carbonic Anhydrase 9 protein, expressed by HEK293 , with C-His labeled tag.
The carbonic anhydrase 9 (CA9) protein plays a crucial role as a catalyst in the conversion of carbon dioxide and water. It promotes the formation of bicarbonate and hydrogen ions (dissociated ions of carbonic acid). Carbonic Anhydrase 9 Protein, Canine (HEK293, hFc) is the recombinant canine-derived Carbonic Anhydrase 9 protein, expressed by HEK293 , with C-hFc labeled tag.
Carbonic Anhydrase 5B Protein, Human (His) expresses in E. coli with a His tag at the N-terminus. Carbonic anhydrase V (CA-V) is a mitochondrial enzyme that provides bicarbonate for pyruvate carboxylase in liver and kidney.
Carbonic Anhydrase 11 Protein, Human (HEK293, His) is an approximately 38.0 kDa carbonic anhydrase 11 protein with a His-flag. Carbonic anhydrases (CAs) are found in many organisms, in which they contribute to several important biological processes.
Carbonic anhydrase 10 (CA10) protein, contrary to its name, lacks catalytic activity. This property distinguishes CA10 from typical carbonic anhydrases, which are known for their ability to catalyze the reversible hydration of carbon dioxide. Carbonic Anhydrase 10 Protein, Human (HEK293 ) is the recombinant human-derived Carbonic Anhydrase 10 protein, expressed by HEK293 , with tag free.
CA12/Carbonic anhydrase 12 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived CA12/Carbonic anhydrase XII protein, expressed by HEK293, with C-His tag.
Carbonic Anhydrase 4 Protein, Mouse (HEK293, His), a recombinant human CAMK1 produced in HEK293 cells, has a His tag at the N-terminus. The Carbonic Anhydrase 4 (CA4) protein is a zinc metalloenzyme that catalyzes the reversible hydration and dehydration of CO2 and HCO3-.
Carbonic Anhydrase 10 Protein, a member of the carbonic anhydrase family, plays a role in the regulation of pH and ion transport. It is expressed in various tissues, including the brain, liver, and kidney. The potential involvement of Carbonic Anhydrase 10 Protein in diseases and its physiological functions make it a subject of interest in biomedical research. Carbonic Anhydrase 10 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Carbonic Anhydrase 10 protein, expressed by HEK293 , with C-His labeled tag.
Carbonic Anhydrase 2 (CA2) catalyzes the reversible hydration of carbon dioxide. Mutations in CA2 are linked to osteopetrosis and renal tubular acidosis. The gene exhibits biased expression in various tissues, notably in the stomach and colon. Two transcript variants, encoding different isoforms, have been identified. Carbonic Anhydrase 2 Protein, Human (HEK293, His) is the recombinant human-derived Carbonic Anhydrase 2 protein, expressed by HEK293 , with C-His labeled tag.
CA12 (or carbonic anhydrase 12) plays a crucial role in the reversible hydration of carbon dioxide, catalyzing its conversion into bicarbonate ions and protons. This enzymatic activity is essential for key physiological processes, including regulating pH and maintaining acid-base balance. CA12/Carbonic Anhydrase 12 Protein, Human (P.pastoris, His) is the recombinant human-derived CA12/Carbonic Anhydrase 12 protein, expressed by P. pastoris , with N-6*His labeled tag.
Carbonic Anhydrase 10 Protein, Human (His) expresses in E. coli with a His tag at the N-terminus. Carbonic anhydrase 10 is an inactive isoform of carbonic anhydrase (CAs).
The carbonic anhydrase 9 (CA9) protein plays a crucial role as a catalyst in the conversion of carbon dioxide and water. It promotes the formation of bicarbonate and hydrogen ions (dissociated ions of carbonic acid). Carbonic Anhydrase 9 Protein, Human (HEK293, His) is the recombinant human-derived Carbonic Anhydrase 9 protein, expressed by HEK293 , with C-6*His labeled tag.
Carbonic Anhydrase 10 Protein, Human (HEK293, His) expresses in HEK293 cell with a His tag at the N-terminus. Carbonic anhydrase 10 is an inactive isoform of carbonic anhydrase (CAs).
The carbonic anhydrase 9 (CA9) protein plays a crucial role as a catalyst in the conversion of carbon dioxide and water. It promotes the formation of bicarbonate and hydrogen ions (dissociated ions of carbonic acid). FITC-Labeled Carbonic Anhydrase 9 Protein, Human (HEK293, His) is the recombinant human-derived FITC-Labeled Carbonic Anhydrase 9 protein, expressed by HEK293, with C-His labeled tag.
The carbonic anhydrase 9 (CA9) protein plays a crucial role as a catalyst in the conversion of carbon dioxide and water. It promotes the formation of bicarbonate and hydrogen ions (dissociated ions of carbonic acid). Carbonic Anhydrase 9 Protein, Human (Biotinylated, HEK293, Avi-His) is the recombinant human-derived Carbonic Anhydrase 9 protein, expressed by HEK293 , with C-Avi, C-6*His labeled tag.
Carbonic Anhydrase 9 Protein catalyzes the reversible hydration of carbon dioxide, essential for converting it to bicarbonate ions and protons, and vice versa. This enzymatic activity is crucial in physiological processes like acid-base balance regulation, respiration, and cellular pH homeostasis. Carbonic Anhydrase 9 Protein is vital for carbon dioxide transport and metabolism, contributing to overall regulation of its levels in the body. Carbonic Anhydrase 9 Protein, Cynomolgus (Biotinylated, HEK293, His-Avi) is the recombinant cynomolgus-derived Carbonic Anhydrase 9 protein, expressed by HEK293 , with C-Avi, C-His labeled tag. The total length of Carbonic Anhydrase 9 Protein, Cynomolgus (Biotinylated, HEK293, His-Avi) is 361 a.a., with molecular weight of 50-55 kDa.
The Carbonic Anhydrase 9 protein is responsible for catalyzing the interconversion between carbon dioxide and water, as well as facilitating the conversion of carbonic acid into its dissociated ions, namely bicarbonate and hydrogen ions. Carbonic Anhydrase 9 Protein, Mouse (HEK293, His) is the recombinant mouse-derived Carbonic Anhydrase 9 protein, expressed by HEK293 , with C-His labeled tag.
Carbonic Anhydrase 9 Protein catalyzes the reversible hydration of carbon dioxide, essential for converting it to bicarbonate ions and protons, and vice versa. This enzymatic activity is crucial in physiological processes like acid-base balance regulation, respiration, and cellular pH homeostasis. Carbonic Anhydrase 9 Protein is vital for carbon dioxide transport and metabolism, contributing to overall regulation of its levels in the body. Carbonic Anhydrase 9 Protein, Cynomolgus (HEK293, His) is the recombinant cynomolgus-derived Carbonic Anhydrase 9 protein, expressed by HEK293 , with C-His labeled tag.
The carbonic anhydrase 9 (CA9) protein plays a crucial role as a catalyst in the conversion of carbon dioxide and water. It promotes the formation of bicarbonate and hydrogen ions (dissociated ions of carbonic acid). Carbonic Anhydrase 9 Protein, Human (HEK293, His-Avi) is the recombinant human-derived Carbonic Anhydrase 9 protein, expressed by HEK293 , with C-Avi, C-His labeled tag.
Acetazolamide-d3 is deuterium labeled Acetazolamide (HY-B0782). Acetazolamide is a carbonicanhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX. Acetazolamide has diuretic, antihypertensive and anti-gonococcal activities.
Zonisamide-d4 is the deuterium labeled Zonisamide. Zonisamide (AD 810) is an inhibitor of zinc enzyme carbonicanhydrase (CA), with Kis of 35.2 nM and 20.6 nM for human mitochondrial isozyme hCA II and hCA V, respectively. Zonisamide has antiepileptic activity. Zonisamide can be used for the rsearch for epilepsy, seizures and Parkinson's disease .
Dorzolamide-d5 is the deuterium labeled Dorzolamide. Dorzolamide (L671152) is a potent carbonicanhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
Dorzolamide-d3 hydrochloride is deuterated labeled Dorzolamide hydrochloride (HY-B0109A). Dorzolamide (L671152) hydrochloride is a potent carbonicanhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
Acetazolamide- 13C2,d3 is the 13C- and deuterium labeled Acetazolamide. Acetazolamide is a carbonicanhydrase (CA) IX inhibitor with an IC50 of 30 nM for hCA IX . Diuretic effects .
Dorzolamide-d5(hydrochloride) (L671152 hydrochloride-d5) is deuterium labeled Dorzolamide (hydrochloride). Dorzolamide (L671152) hydrochloride is a potent carbonicanhydrase II inhibitor, with IC50 values of 0.18 nM and 600 nM for red blood cell CA-II and CA-I respectively. Dorzolamide possesses anti-tumor activity .
Brinzolamide-d5 (hydrochloride) is the deuterium labeled Brinzolamide hydrochloride . Brinzolamide (AL-4862) hydrochloride is a selective carbonicanhydrase II inhibitor with an IC50 value of 3.2 nM. Brinzolamide hydrochloride reduces intraocular pressure (IOP) by inhibiting ciliary CA-II and decreasing atrial fluid secretion. Brinzolamide hydrochloride can be used in glaucoma disease research .
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
MedchemExpress Validation 03
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
MedchemExpress Validation 04
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedchemExpress Validation
Western blot analysis of extracts from THP-1(lane 2(20μg), Jurkat (lane 3(20μg) and NIH3T3(lane 4(20μg) using FOXO1A (HY-P80132) Rabbit mAb. Proteins were transferred
to a PVDF membrane and blocked with 5% non-fat milk in TBST for 2 hour at room temperature. The primary antibody (1/1000) and Loading control antibody (Beta Actin, HY-P80438, 1/10000) was
used in 5% non-fat milk in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (1/10000) was used for 1 hour at room temperature.
MedChemExpress values your privacy and your trust is important to us. We use cookies to enhance your website experience. Some cookies are necessary to run the website.
Privacy and Cookie Policy
